Sign In
Buy ITOS
$10.15
+0 (+0%)
At Close: Nov 28, 2025
Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher
11:18am, Monday, 13'th Nov 2023
iTeos Therapeutics, Inc. (ITOS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agree
Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know
11:16am, Friday, 10'th Nov 2023
The mean of analysts' price targets for iTeos Therapeutics, Inc. (ITOS) points to a 304.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
07:00am, Tuesday, 07'th Nov 2023
- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose
iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail
09:00am, Saturday, 04'th Nov 2023
iTeos Therapeutics is a clinical-stage biotech focused on developing immunotherapies for solid tumors, with a focus on non-small cell lung cancer (NSCLC). Their most advanced project is belrestotug, a
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?
06:01am, Monday, 16'th Oct 2023
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be
iTeos to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 06'th Sep 2023
WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 06, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall
03:55pm, Friday, 25'th Aug 2023
iTeos Therapeutics focuses on developing immuno-oncology treatments for cancer patients, with a focus on TIGIT-targeted therapies. Roche's accidental disclosure of positive data on its anti-TIGIT ther
iTeos Therapeutics: Trading Under Cash Value
10:04am, Sunday, 04'th Jun 2023
Today, we circle back on small oncology concern iTeos Therapeutics, Inc. for the first time since last July. The company is advancing its two primary compounds in its pipeline and has a potentially lu
ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates
09:55am, Wednesday, 10'th May 2023
ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to earnings of $1.82 per share a year ago.
The 7 Most Undervalued Stocks You Need to Know About
03:38pm, Tuesday, 18'th Apr 2023
Heading into unchartered territory in the market, investors may take comfort in acquiring the most undervalued stocks. Primarily, the less-popular enterprises offer the advantage of being exactly that
7 Small-Cap Stocks That Are Flying Under the Radar
03:32pm, Tuesday, 04'th Apr 2023
While most financial advisors direct you toward established, large-capitalization companies because of their relatively safer business profile, small-cap stocks to buy may pack quite a punch for speci
7 Dirt-Cheap Stocks Sitting in the Sweet Spot
02:25pm, Thursday, 23'rd Mar 2023
While it's always nice to get a discount, with cheap stocks, it may be better to go for enterprises sitting in the sweet spot; that is, publicly traded securities that are cheap but not too cheap wher
ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates
09:56am, Wednesday, 15'th Mar 2023
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the s
The Top 7 Growth Stocks in Biotech
06:57pm, Friday, 03'rd Mar 2023
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
iTeos Therapeutics: Able To Pull In Big Pharma Deals, Needs Follow-Through
02:41pm, Thursday, 02'nd Mar 2023
iTeos Therapeutics, Inc. has a major deal with GSK, but a rival drug failed, bringing iTeos Therapeutics down. This happened once before with another program.
